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Abstract
 
An allograft is often considered an immunologically inert playing field on which host leukocytes
assemble and wreak havoc. However, we demonstrate that graft-specific physiologic responses
to early injury initiate and promulgate destruction of vascularized grafts. Serial analysis of al-
lografts showed that intragraft expression of the three chemokine ligands for the CXC chemo-
kine receptor CXCR3 was induced in the order of interferon (IFN)-
 
g
 
–inducible protein of 10
kD (IP-10, or CXCL10), IFN-inducible T cell 
 
a
 
-chemoattractant (I-TAC; CXCL11), and
then monokine induced by IFN-
 
g
 
 (Mig, CXCL9). Initial IP-10 production was localized to
endothelial cells, and only IP-10 was induced by isografting. Anti–IP-10 monoclonal antibodies
prolonged allograft survival, but surprisingly, IP-10–deficient (IP-10
 
2
 
/
 
2
 
) mice acutely rejected
allografts. However, though allografts from IP-10
 
1
 
/
 
1
 
 mice were rejected by day 7, hearts from
IP-10
 
2
 
/
 
2
 
 mice survived long term. Compared with IP-10
 
1
 
/
 
1
 
 donors, use of IP-10
 
2
 
/
 
2
 
 donors
reduced intragraft expression of cytokines, chemokines and their receptors, and associated leuko-
cyte infiltration and graft injury. Hence, tissue-specific generation of a single chemokine in re-
sponse to initial ischemia/reperfusion can initiate progressive graft infiltration and amplification
of multiple effector pathways, and targeting of this proximal chemokine can prevent acute re-
jection. These data emphasize the pivotal role of donor-derived IP-10 in initiating allore-
sponses, with implications for tissue engineering to decrease immunogenicity, and demonstrate
that chemokine redundancy may not be operative in vivo.
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Introduction
 
Chemokine expression during allograft rejection, first doc-
umented since 1993 (1), has since been demonstrated in
many experimental and clinical transplant studies (2).
Though the methods for chemokine detection have ranged
from immunohistology to reverse transcription PCR, the
recent advent of commercial RNase protection assay kits
has provided a standardized means for the detection of
chemokine and chemokine receptor mRNA, and has
proven a boon to the field. However, there are still very
few mechanistic studies concerning the role of chemokine
pathways in alloresponses (2).
In the first mechanistic study of the role of a chemokine
receptor in the pathogenesis of allograft rejection, analysis of
cardiac allograft rejection in CC chemokine receptor
1–deficient (CCR1
 
2
 
/
 
2
 
) versus CCR1
 
1
 
/
 
1
 
 mice showed
that CCR1 contributed to the development of acute and
chronic allograft rejection (3). Though by itself, CCR1 de-
ficiency had only modest effects of rejection of fully MHC-
mismatched allografts, an absolute requirement for CCR1
in the development of chronic rejection was shown in re-
cipients treated with subtherapeutic courses of cyclosporin
A or CD4 mAb. Beneficial effects on allograft survival were
also noted using CCR2- and CCR5-deficient allograft re-
cipients (2). However, the most profound effects reported
so far involved targeting of the CXC chemokine receptor,
CXCR3, which is expressed by activated Th1 cells and
NK cells (4). Use of a blocking anti-CXCR3 mAb or
CXCR3
 
2
 
/
 
2
 
 mice was shown to prevent acute rejection,
with a mean allograft survival of almost 60 d in CXCR3
 
2
 
/
 
2
 
recipients versus 7 d in CXCR3
 
1
 
/
 
1 
 
controls (5).
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In vitro studies have documented a plethora of chemo-
kines and receptors, with many chemokines binding to the
same receptor and individual chemokines binding to multi-
ple receptors, such that notions of chemokine redundancy
and doubts as to the value of ligand targeting, in particular,
are widespread (6). Given the importance of CXCR3 to al-
loresponses and detection of intragraft mRNA expression of
each of its three ligands, IFN-
 
g
 
–inducible protein (IP)-10
(7), IFN-inducible T cell 
 
a
 
-chemoattractant (I-TAC; refer-
ence 8), and Mig (9), during development of acute rejec-
tion (5), we asked whether these ligands might show tem-
poral or spatial differences in their expression that would
help explain their biologic roles. The results of our studies
lead to a rationale for targeting selected chemokines in vivo.
 
Materials and Methods
 
Transplantation.
 
IP-10
 
2
 
/
 
2
 
 mice were generated in the labora-
tory of A.D. Luster. Heterotopic vascularized cardiac allografting
was performed using fully MHC-mismatched BALB/c (H-2
 
d
 
)
and C57BL/6
 
 3 
 
129Sv/J (H-2
 
b
 
) mice (10). B6/129 mice were
IP-10
 
2
 
/
 
2
 
 versus age- and sex-matched littermate IP-10
 
1
 
/
 
1
 
 mice.
BALB/c and additional B6/129, plus control C57BL/6 (H-2
 
b
 
)
and 129 (H-2
 
b
 
) mice, were obtained commercially (The Jackson
Laboratory); all mice used were between 6 and 10 wk of age. Ad-
ditional recipients were treated with neutralizing hamster (11) or
rat (BD PharMingen) anti–mouse IP-10 mAbs, or corresponding
hamster or rat IgG (Jackson ImmunoResearch Laboratories) by
intraperitoneal injection of 200 
 
m
 
g every second day; therapy was
begun at engraftment and stopped at 14 d after transplant. In pre-
liminary studies, this dose of mAb resulted in serum trough levels
at 48 h which exceeded the IC
 
50
 
 for in vitro neutralization of IP-
10–mediated chemotaxis of mouse CXCR3
 
1
 
 spleen cells (data
not shown).
 
Immunopathology.
 
Histologic evaluation or allografts was un-
dertaken using hematoxylin and eosin (H&E)-stained paraffin sec-
tions. Infiltrating host leukocytes and chemokine expression were
detected in serially harvested allografts by immunoperoxidase
staining of cryostat sections using rat anti–mouse cell lineage–spe-
cific mAbs (BD PharMingen), rat anti–mouse CXCR3 mAb (5),
and polyclonal anti–I-TAC and anti-Mig Abs (R&D Systems; ref-
erence 12), with quantitative analysis of labeled cells (3). Control
sections were stained with isotype-matched mAbs or normal IgG.
 
Cellular and Molecular Studies.
 
Splenocytes were activated with
Con A and cultured in IL-2 to generate CXCR3
 
1
 
 T cell blasts for
use in chemotaxis studies (13). Methods for the production of
cDNA probes for murine IP-10, I-TAC, and Mig, and an RNase
protection assay probe for murine CXCR3; methods for RNA
isolation, use of Northern blot analysis, and RNase protection as-
says for intragraft cytokines, chemokines, and their receptors (BD
PharMingen), with normalization to glyceraldehyde 3-phosphate
dehydrogenase or L32 genes, have been reported previously (3, 5).
 
Results and Discussion
 
Given the importance of CXCR3 expression to the de-
velopment of acute allograft rejection in the current model
(5), we undertook a serial study of mRNA expression
of the three known CXCR3 chemokine ligands. Serial
Northern blot analyses showed that no CXCR3 chemo-
kine ligand mRNA expression was seen in normal hearts
and only IP-10 was induced in allografts or isografts within
24 h of transplantation (Fig. 1 a). Subsequent intracardiac
expression of I-TAC and Mig mRNA was detected at day
3 after transplant, in conjunction with IFN-
 
g
 
 mRNA ex-
pression (Fig. 1 a). Immunohistologic studies of corre-
Figure 1. Rationale for targeting of selected CXCR3 ligands in al-
lograft recipients. (a) Northern blot analysis of cardiac expression of the
CXCR3 ligands, IP-10, I-TAC, and Mig, after isografting (H2b®H2b; 1 d)
or allografting (H2d®H2b; 1, 3, and 7 d). IP-10 mRNA was induced in
both isografts and allografts, whereas I-TAC and Mig mRNA were re-
stricted to allografts and were first seen at 3 d after transplant. (b) Immu-
nohistologic localization of CXCR3 ligands in portions of the same
isografts or allografts as shown in panel a. IP-10 production in isografts
and allografts was initially confined to cardiac endothelial cells, whereas
by day 3, IP-10 was widely expressed by graft endothelial cells and infil-
trating leukocytes; I-TAC was focally expressed by endothelial cells and
leukocytes, and Mig was confined to leukocytes, especially large inflam-
matory macrophages. Cryostat sections, hematoxylin counterstain; origi-
nal magnifications: 3300. For both Northern blot analysis and immuno-
histologic studies, data are representative of the results from three samples
per group per time point. 
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sponding samples showed that IP-10 expression was ini-
tially localized to graft endothelial cells, whereas by day 3
(and later) IP-10 was also expressed by infiltrating leuko-
cytes (Fig. 1 b). I-TAC was detected focally within mi-
crovascular endothelial cells and some leukocytes at day 3,
whereas Mig staining was largely confined to infiltrating
large inflammatory macrophages (Fig. 1 b).
Since IP-10 was the first CXCR3 ligand detected after
allografting and was the sole CXCR3 ligand induced by
isografting, we tested the effects of ongoing intraperitoneal
administration of neutralizing mAbs to IP-10, beginning at
the time of transplantation. Both anti–IP-10 mAbs tested
resulted in a doubling of cardiac allograft survival time over
recipients treated with control IgG (
 
P
 
 , 
 
0.01; Fig. 2 a).
This occurred whether H2
 
d
 
®
 
H2
 
b
 
 transplantation or the re-
verse donor
 
 
 
to recipient combination was used, suggesting
the importance of this ligand to allograft rejection indepen-
dent of the genetic background of the mouse strain and as-
sociated predisposition to develop Th1 or Th2 predominant
responses. Also, we tested the effects of a complete lack of
IP-10 on alloresponses using IP-10
 
2
 
/
 
2 
 
mice generated by
homologous recombination. To our surprise, IP-10
 
2
 
/
 
2
 
 re-
cipients rejected cardiac allografts at the same rate as IP-10
 
1
 
/
 
1
 
recipients (Fig. 2 b). However, reasoning that anti–IP-10
mAb therapy may have prolonged allograft survival by neu-
tralizing chemokine being produced by graft endothelial
cells, we tested the survival of cardiac allografts from IP-
10
 
2
 
/
 
2
 
 versus IP-10
 
2
 
/
 
2
 
 donors. Again surprisingly, whereas
wild-type grafts were rejected normally, IP-10
 
2
 
/
 
2
 
 donor
hearts survived for 
 
.
 
40 d (
 
P 
 
,
 
 0.001).
To determine how the absence of a single chemokine in
donor tissue might have such profound effects on allograft
survival, we undertook immunohistologic studies of rele-
vant intragraft cell populations during the initial period of
engraftment. In hearts from IP-10
 
1
 
/
 
1
 
 donors, small num-
Figure 2. Effects of IP-10 targeting on allograft survival. (a) Cardiac al-
lografts across a full MHC disparity were rejected in z7 d, regardless of
the choice of donor or recipient, but allograft survival was prolonged by
use of neutralizing rat anti–mouse IP-10 mAb (*P , 0.01). Comparable
prolongation was seen using a hamster anti–mouse IP-10 mAb. (b) IP-
102/2 mice reject cardiac allografts at the same rate as IP-101/1 recipients;
however, the survival of allografted hearts from IP-102/2 mice is mark-
edly prolonged compared with hearts from IP-101/1 mice. Data from n =
6 transplants/group for each of the 10 groups shown; *P , 0.001.
Figure 3. Early graft infiltration by host leukocytes is modulated in IP-
102/2 donor hearts, as shown by quantitative immunohistologic analysis
of intragraft CXCR31 cells, mAb DX51 NK cells, and CD31 T cells
present at days 0, 1, 3, and 7 after transplant. Data (mean 6 SD) from
counting of 20 consecutive fields/graft and 3 allografts/group. *Signifi-
cantly different cell numbers in IP-101/1 donor hearts versus IP-102/2
samples (*P , 0.05; **P , 0.01; ***P , 0.005). 
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bers of CXCR3
 
1
 
 cells began to accumulate along the graft
vasculature within 1 d of transplantation, were doubled in
number by 3 d, and peaked at the time of rejection 
 
z
 
7 d af-
ter transplant (Fig. 3). Since CXCR3 is primarily expressed
by NK cells and activated T cells (14), we assessed the num-
bers of each of these cell types. NK cells infiltrated IP-10
 
1
 
/
 
1
 
allografts rapidly after transplant, with a peak by day 3 and
decline towards baseline thereafter, whereas CD3
 
1
 
 T cells
were first detected in substantial numbers by day 3 and con-
tinued to increase thereafter. In contrast to the events in IP-
10
 
1
 
/
 
1
 
 donor grafts, allografts from IP-10
 
2
 
/
 
2
 
 donors showed
significantly less infiltration by CXCR3
 
1
 
 leukocytes (Fig.
3), and largely lacked the early wave of infiltrating leuko-
cytes, primarily NK cells, that was seen in control grafts. An
influx of NK cells within 2–3 d of allografting has long been
noted in clinical transplant recipients (15), though the
mechanisms responsible have not been explored. Data from
rodent skin (16) and cardiac (17) allograft models indicate
that an early influx of NK or CD8
 
1
 
 T cells can promote al-
lograft chemokine production as a result of IFN-
 
g expres-
sion, but the key role of IP-10 in the initiation of this cas-
cade of events was not demonstrated previously.
Histologic and immunohistologic comparisons at day 7
after transplant were performed to assess the effects of lack
of donor IP-10 on key histopathologic and immunopatho-
logic manifestations of allograft rejection. Whereas H&E-
stained sections of allografts from IP-101/1 donors showed
widespread myocardial necrosis and leukocyte infiltration,
allografts from IP-102/2 were essentially normal (Fig. 4 a).
IP-11/1 donor grafts contained extensive labeling for all
three CXCR3 ligands, but no staining was seen in grafts
from IP-102/2 donors (Fig. 4 b). Consistent with the H&E
findings, immunohistologic analysis showed that lack of IP-
10 expression in donor hearts led to significantly reduced
CD451 leukocyte infiltration, involving significant reduc-
tions in CD41 and CD81 T cells subsets, macrophages, and
intragraft immune activation, as reflected by expression of
IL-2R (CD25; Fig. 4 c). At day 7, both groups showed
only negligible NK cell, B cell, or neutrophil infiltration.
Since allografts from IP-101/1 but not IP-102/2 donors
were rejected by 7–8 d after transplant, we used RNase
protection assays to compare intragraft cytokine, chemo-
kine, and chemokine receptor mRNA expression at day 7
(Fig. 5). Compared with IP-101/1 donors, use of IP-102/2
Figure 4. Mechanisms underlying the beneficial effects of targeting donor tissue IP-10 expression. (a) Histology showing acute rejection with exten-
sive mononuclear cell infiltration, vascular injury, and myocyte necrosis in grafts from IP-101/1 donors versus almost normal histology in grafts from IP-
102/2 donors (day 7 after transplant). Paraffin sections, hematoxylin; original magnifications: 3300. (b) Immunohistologic detection of IP-10, I-TAC,
and Mig in cardiac allografts from IP-101/1 but not IP-102/2 donors (day 7 after transplant). Cryostat sections, hematoxylin; original magnifications:
3450. (c) Immunohistologic analysis showed significant reduction in recruitment of intragraft CD451 cells (all leukocytes), CD4 and CD8 T cell subsets,
macrophages, and IL-2R1 (CD251) cells in allografts from IP-102/2 versus IP-101/1 donors at day 7 after transplantation. Data (mean 6 SD) from
counting of 20 consecutive fields/graft and 3 grafts/group. *Significantly reduced cell numbers versus controls (*P , 0.05; **P , 0.01; ***P , 0.005).979 Hancock et al. Brief Definitive Report
reperfusion injury (23) to blood vessels induce IP-10 pro-
duction, and the IP-10 promoter has a functional nuclear
factor kB binding site (24), whereas I-TAC and Mig do
not. Moreover, in studies to be reported separately, we
have found that inhibition of nuclear factor kB activation
prevents intragraft expression of IP-10 and prolongs al-
lograft survival.
In summary, we have begun to explore the significance
in rejecting allografts of three ligands for the one receptor
that, based on data using gene targeting and neutralizing
mAbs, appears of greatest importance in mediating leuko-
cyte recruitment to rejecting allografts. Of the three
chemokine ligands for CXCR3, only IP-10 is induced by
surgical manipulation, though the relative roles of isch-
emia/reperfusion injury, hypoxia, and other potential fac-
tors in mediating this rapid expression by endothelial cells
of both isografts and allografts are not yet known. We
found that endothelial IP-10 expression promotes the ini-
tial local recruitment of NK cells and shortly thereafter,
host T cells. The current findings suggest that the produc-
tion of IFN-g by these rapidly recruited CXCR31 cells
serves to amplify and extend chemokine production, lead-
ing to increasing IP-10 and induction of I-TAC and Mig
production by graft endothelial cells and host leukocytes.
Though the effects of targeting of I-TAC and Mig in this
system remain to be determined, our data emphasize the
pivotal role of donor-derived IP-10 induction in initiation
and amplification of the host alloresponses which lead to
acute rejection. Further understanding of this sequence of
events may be of therapeutic importance in allotransplanta-
Figure 5. Effects of lack of donor-derived IP-10 on intragraft events. (a) RNase
protection assays of intragraft cytokine, chemokine, and chemokine receptor
mRNA expression, comparing grafts from IP-101/1 (lanes 1–3) to IP-102/2 (lanes
4–6) donors at day 7 after transplant. (b) Quantitative analysis of RNase protection
assay data, showing the significant depression of intragraft IFN-g, chemokine, and
CC and CXC chemokine receptor mRNA expression in IP-102/2 versus IP-101/1
donor hearts. Data are from three transplants/group, as shown, and experiments
were performed twice with comparable findings. *P , 0.05; **P , 0.01; ***P ,
0.005; ****P , 0.001.
hearts significantly decreased intragraft expression of IFN-g
mRNA, as well as that of multiple chemokine mRNAs
(and that of their receptors), including macrophage inflam-
matory protein (MIP)-1a (CCR1, CCR5), MIP-1b
(CCR5), and regulated upon activation normal T cell ex-
pressed and secreted (RANTES; CCR1, CCR5). IP-102/2
hearts also had significantly decreased CXCR3 mRNA ex-
pression, consistent with the immunohistologic data (Fig.
3), and decreased CCR2 mRNA. Given that mRNA lev-
els of the main CCR2 ligand, monocyte chemotactic pro-
tein 1, showed a trend towards increased rather than de-
creased levels in IP-102/2 hearts, the decreased intragraft
CCR2 mRNA levels likely reflect secondary effects, e.g.,
decreased recruitment of cells that happen to bear multiple
chemokine receptors, including CCR2, and CXCR4
whose mRNA levels were also decreased.
There may well be multiple mechanisms responsible for
the remarkable prolongation of survival of allografts from
IP-102/2 donors, in view of the decreased early posttrans-
plant graft infiltration, absence of acute rejection, and pro-
longed allograft survival. Our data suggest that IP-10–
dependent effects on initial NK production of IFN-g (18),
T cell activation and cytokine production (19), T cell hom-
ing and recirculation (20), and development of multiple ef-
fector cell pathways (21) may be involved, though whether
any one mechanism is paramount is unknown. However,
there are reports concerning the proximal role of IP-10 in
other inflammatory responses, and data relevant to under-
standing why IP-10 appears to be selectively induced after
transplantation. Both mechanical injury (22) and ischemia/980 Donor-derived IP-10 and Acute Rejection
tion, as well as in the fields of tissue engineering and xe-
notransplantation. In the latter case, development of donors
deficient in production of IP-10 may facilitate the control
of host T cell responses in xenograft recipients (25).
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